These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 9113512)
1. A gene delivery system activatable by disease-associated matrix metalloproteinases. Peng KW; Morling FJ; Cosset FL; Murphy G; Russell SJ Hum Gene Ther; 1997 Apr; 8(6):729-38. PubMed ID: 9113512 [TBL] [Abstract][Full Text] [Related]
2. Lack of specificity of cell-surface protease targeting of a cytotoxic hyperfusogenic gibbon ape leukaemia virus envelope glycoprotein. Kirkham LA; Bateman AR; Melcher AA; Vile RG; Fielding AK J Gene Med; 2002; 4(6):592-600. PubMed ID: 12439851 [TBL] [Abstract][Full Text] [Related]
3. A hyperfusogenic gibbon ape leukemia envelope glycoprotein: targeting of a cytotoxic gene by ligand display. Fielding AK; Chapel-Fernandes S; Chadwick MP; Bullough FJ; Cosset FL; Russell SJ Hum Gene Ther; 2000 Apr; 11(6):817-26. PubMed ID: 10779159 [TBL] [Abstract][Full Text] [Related]
4. Masking of retroviral envelope functions by oligomerizing polypeptide adaptors. Morling FJ; Peng KW; Cosset FL; Russell SJ Virology; 1997 Jul; 234(1):51-61. PubMed ID: 9234946 [TBL] [Abstract][Full Text] [Related]
5. Targeting the cytotoxicity of fusogenic membrane glycoproteins in gliomas through protease-substrate interaction. Johnson KJ; Peng KW; Allen C; Russell SJ; Galanis E Gene Ther; 2003 May; 10(9):725-32. PubMed ID: 12704411 [TBL] [Abstract][Full Text] [Related]
7. Selective transduction of protease-rich tumors by matrix-metalloproteinase-targeted retroviral vectors. Peng KW; Vile R; Cosset FL; Russell S Gene Ther; 1999 Sep; 6(9):1552-7. PubMed ID: 10490764 [TBL] [Abstract][Full Text] [Related]
8. Expression of immunoreactive matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in human normal livers and primary liver tumors. Terada T; Okada Y; Nakanuma Y Hepatology; 1996 Jun; 23(6):1341-4. PubMed ID: 8675149 [TBL] [Abstract][Full Text] [Related]
9. Targeting of retroviral vectors through protease-substrate interactions. Nilson BH; Morling FJ; Cosset FL; Russell SJ Gene Ther; 1996 Apr; 3(4):280-6. PubMed ID: 8732159 [TBL] [Abstract][Full Text] [Related]
10. Inverse targeting of retroviral vectors: selective gene transfer in a mixed population of hematopoietic and nonhematopoietic cells. Fielding AK; Maurice M; Morling FJ; Cosset FL; Russell SJ Blood; 1998 Mar; 91(5):1802-9. PubMed ID: 9473249 [TBL] [Abstract][Full Text] [Related]
11. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in human gliomas. Nakano A; Tani E; Miyazaki K; Yamamoto Y; Furuyama J J Neurosurg; 1995 Aug; 83(2):298-307. PubMed ID: 7616276 [TBL] [Abstract][Full Text] [Related]
12. Adenoviral vectors expressing fusogenic membrane glycoproteins activated via matrix metalloproteinase cleavable linkers have significant antitumor potential in the gene therapy of gliomas. Allen C; McDonald C; Giannini C; Peng KW; Rosales G; Russell SJ; Galanis E J Gene Med; 2004 Nov; 6(11):1216-27. PubMed ID: 15459967 [TBL] [Abstract][Full Text] [Related]
13. Differentiated thyroid cancer cell invasion is regulated through epidermal growth factor receptor-dependent activation of matrix metalloproteinase (MMP)-2/gelatinase A. Yeh MW; Rougier JP; Park JW; Duh QY; Wong M; Werb Z; Clark OH Endocr Relat Cancer; 2006 Dec; 13(4):1173-83. PubMed ID: 17158762 [TBL] [Abstract][Full Text] [Related]
14. Tissue inhibitor of metalloproteinases-4 inhibits but does not support the activation of gelatinase A via efficient inhibition of membrane type 1-matrix metalloproteinase. Bigg HF; Morrison CJ; Butler GS; Bogoyevitch MA; Wang Z; Soloway PD; Overall CM Cancer Res; 2001 May; 61(9):3610-8. PubMed ID: 11325829 [TBL] [Abstract][Full Text] [Related]
15. Analysis of tissue inhibitor of metalloproteinases-2 effect on pro-matrix metalloproteinase-2 activation by membrane-type 1 matrix metalloproteinase using baculovirus/insect-cell expression system. Jo Y; Yeon J; Kim HJ; Lee ST Biochem J; 2000 Feb; 345 Pt 3(Pt 3):511-9. PubMed ID: 10642509 [TBL] [Abstract][Full Text] [Related]
16. Differential expression of membrane-type matrix metalloproteinase and its correlation with gelatinase A activation in human malignant brain tumors in vivo and in vitro. Yamamoto M; Mohanam S; Sawaya R; Fuller GN; Seiki M; Sato H; Gokaslan ZL; Liotta LA; Nicolson GL; Rao JS Cancer Res; 1996 Jan; 56(2):384-92. PubMed ID: 8542596 [TBL] [Abstract][Full Text] [Related]
17. Retroviral vector targeting human cells via c-Kit-stem cell factor interaction. Yajima T; Kanda T; Yoshiike K; Kitamura Y Hum Gene Ther; 1998 Apr; 9(6):779-87. PubMed ID: 9581901 [TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor-like ligands differentially up-regulate matrix metalloproteinase 9 in head and neck squamous carcinoma cells. O-charoenrat P; Modjtahedi H; Rhys-Evans P; Court WJ; Box GM; Eccles SA Cancer Res; 2000 Feb; 60(4):1121-8. PubMed ID: 10706134 [TBL] [Abstract][Full Text] [Related]
19. Enhanced production of matrix metalloproteinases and activation of matrix metalloproteinase 2 (gelatinase A) in human gastric carcinomas. Nomura H; Fujimoto N; Seiki M; Mai M; Okada Y Int J Cancer; 1996 Feb; 69(1):9-16. PubMed ID: 8600068 [TBL] [Abstract][Full Text] [Related]
20. Enhancement of membrane-type 1-matrix metalloproteinase (MT1-MMP) production and sequential activation of progelatinase A on human squamous carcinoma cells co-cultured with human dermal fibroblasts. Sato T; Iwai M; Sakai T; Sato H; Seiki M; Mori Y; Ito A Br J Cancer; 1999 Jun; 80(8):1137-43. PubMed ID: 10376963 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]